The Mild Brain Injury Atypical Symptoms (mBIAS) scale in a mixed clinical sample
Authors:
- 9 May 2016
- journal article
- research article
- Published by Taylor & Francis in Journal of Clinical and Experimental Neuropsychology
- Vol. 38 (7) , 721-729
Abstract
Introduction: The Mild Brain Injury Atypical Symptoms (mBIAS) scale was developed as a symptom validity test (SVT) for use with patients following mild traumatic brain injury. This study was the first to examine the clinical utility of the mBIAS in a mixed clinical sample presenting to a Department of Veterans Affairs (VA) neuropsychology clinic. Method: Participants were 117 patients with mixed etiologies (85.5% male; age: M = 39.2 years, SD = 11.6) from a VA neuropsychology clinic. Participants were divided into pass/fail groups using two different SVT criteria, based on select validity scales from the Minnesota Multiphasic Personality Inventory–2 (MMPI–2): first, Infrequency Scale (F) scores: (a) MMPI–F–Fail (n = 21) and (b) MMPI–F–Pass (n = 96); and, second, Symptom Validity Scale (FBS) scores: (a) MMPI–FBS–Fail (n = 36) and (b) MMPI–FBS–Pass (n = 81). Results: The mBIAS demonstrated good internal consistency, and each item contributed meaningfully to the total score. At a symptom exaggeration base rate of 35%, an mBIAS cutoff of ≥11 was optimal for screening symptom exaggeration when groups were classified using both F and FBS scales. This cutoff score resulted in very high specificity (.89 to .94); moderate–high positive predictive power (.71 to .75) and negative predictive power (.72 to .79); and low–moderate sensitivity (.31 to .57). At all base rates of probable somatic exaggeration, a cutoff of ≥16 resulted in perfect specificity and positive predictive power, but very low sensitivity. Conclusions: The mBIAS has potential for use in samples outside of mild traumatic brain injury. In settings where the symptom exaggeration base rate is 35%, a cutoff of ≥11 may be used as a “red flag” for further evaluation, but should not be relied on for clinical decision making. At all base rates of probable somatic exaggeration, psychologists with patients who score ≥16 can be confident that those patients were exaggerating. Importantly, however, this cutoff may fail to identify a large proportion of patients who are exaggerating.Keywords
This publication has 19 references indexed in Scilit:
- Clinical utility of the Neurobehavioral Symptom Inventory validity scales to screen for symptom exaggeration following traumatic brain injuryJournal of Clinical and Experimental Neuropsychology, 2015
- Examination of the Mild Brain Injury Atypical Symptom Scale and the Validity-10 Scale to detect symptom exaggeration in US military service membersJournal of Clinical and Experimental Neuropsychology, 2015
- Utility of the Mild Brain Injury Atypical Symptoms Scale to detect symptom exaggeration: An analogue simulation studyJournal of Clinical and Experimental Neuropsychology, 2013
- Influence of poor effort on neuropsychological test performance in U.S. military personnel following mild traumatic brain injuryJournal of Clinical and Experimental Neuropsychology, 2012
- Utility of the Mild Brain Injury Atypical Symptoms Scale as a Screening Measure for Symptom Over-Reporting in Operation Enduring Freedom/Operation Iraqi Freedom Service Members with Post-Concussive ComplaintsArchives of Clinical Neuropsychology, 2011
- “Good Old Days” Bias Following Mild Traumatic Brain InjuryThe Clinical Neuropsychologist, 2009
- Comparison of the MMPI-2 Restructured Demoralization Scale, Depression Scale, and Malingered Mood Disorder Scale in Identifying Non-credible Symptom Reporting in Personal Injury Litigants and Disability ClaimantsThe Clinical Neuropsychologist, 2009
- Differential sensitivity of the Response Bias Scale (RBS) and MMPI-2 validity scales to memory complaintsThe Clinical Neuropsychologist, 2008
- Symptom validity assessment: Practice issues and medical necessityNAN Policy & Planning CommitteeArchives of Clinical Neuropsychology, 2005
- Exaggerated Pain Report in Litigants With Malingered Neurocognitive DysfunctionThe Clinical Neuropsychologist, 2003